Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
1.600
-0.060 (-3.61%)
At close: Mar 28, 2025, 4:00 PM
1.611
+0.011 (0.69%)
After-hours: Mar 28, 2025, 7:55 PM EDT
Agenus Revenue
In the year 2024, Agenus had annual revenue of $103.46M, down -33.81%. Agenus had revenue of $26.84M in the quarter ending December 31, 2024, a decrease of -67.98%.
Revenue (ttm)
$103.46M
Revenue Growth
-33.81%
P/S Ratio
0.33
Revenue / Employee
$327,415
Employees
316
Market Cap
40.49M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AGEN News
- 5 days ago - Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025 - Business Wire
- 11 days ago - Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation - Business Wire
- 19 days ago - Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program - Business Wire
- 4 weeks ago - Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications - Business Wire
- 4 weeks ago - Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference - Business Wire
- 4 weeks ago - Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report - Business Wire
- 4 weeks ago - Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting - Business Wire